Amine and peptide levels have been measured in brain samples form Parkinson's Disease (PD) patients as well as from controls both with and without Lewy bodies.
Amine measurements showed that dopamine was reduced more in putamen than in caudate nucleus and that ventral subregions showed less alteration than dorsal subregions in PD. However, no differences were found between control samples with or without Lewy bodies.
Peptide measurements showed parallel changes in striatal regions of PD samples and those controls with Lewy bodies. These alterations are neither secondary to dopamine nigrostriatal pathway degeneration nor antiparkinsonian therapy.
Since the use of peptides as coadjuvants in PD therapy has been suggested, peptide receptors have also been studied.
Funding SchemeCSC - Cost-sharing contracts
SE5 8AF London